<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Sharpe | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/toothlip2/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/toothlip2/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Sharpe.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">becb42030f01c7a14e1bb338dd2d11e8</guid>
				<title>Sharpe posted an update: To translate recent advances in medical device [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41828/</link>
				<pubDate>Sat, 08 Feb 2025 11:06:19 -0800</pubDate>

									<content:encoded><![CDATA[<p>To translate recent advances in medical device interoperability research into clinical practice, standards are being developed that specify precise requirements towards the network representation of particular medical devices connecting through ISO/IEEE 11073 SDC. The present contribution supplements this protocol standard with specific models for&hellip;<span class="activity-read-more" id="activity-read-more-41828"><a href="http://www.nationalboardinstitute.com/activity/p/41828/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e4d101c61934d6d45972c0413e290ec9</guid>
				<title>Sharpe posted an update: Early prediction of elimination pathways for new chemical [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/40384/</link>
				<pubDate>Thu, 06 Feb 2025 16:06:50 -0800</pubDate>

									<content:encoded><![CDATA[<p>Early prediction of elimination pathways for new chemical entities can have a profound impact on drug discovery programs. The recently proposed Extended Clearance Classification System (ECCS) is a step in the right direction, providing a framework to help identify the major elimination pathway of a drug. A list of 42 Amgen small molecules was&hellip;<span class="activity-read-more" id="activity-read-more-40384"><a href="http://www.nationalboardinstitute.com/activity/p/40384/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">66284f724792afa46cbe8f57e2a6e063</guid>
				<title>Sharpe posted an update: 9%) and ESUS (44% versus 34.7%), this difference did not [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38522/</link>
				<pubDate>Tue, 04 Feb 2025 11:48:58 -0800</pubDate>

									<content:encoded><![CDATA[<p>9%) and ESUS (44% versus 34.7%), this difference did not reach significance after Bonferroni-adjustment for multiple comparisons (P&gt; .05, each). There was no difference in the prevalence of an MTSP among subjects with known (n = 11/51; 21.6%) versus subsequently diagnosed (n = 1/3; 33.3%) AF (P= .54). CONCLUSIONS Our findings indicate that the kno&hellip;<span class="activity-read-more" id="activity-read-more-38522"><a href="http://www.nationalboardinstitute.com/activity/p/38522/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7f99c2bd662b7e978f99bbfb243d0aa3</guid>
				<title>Sharpe posted an update: This study was focused on the development and validation of [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36788/</link>
				<pubDate>Sun, 02 Feb 2025 11:58:08 -0800</pubDate>

									<content:encoded><![CDATA[<p>This study was focused on the development and validation of a Mid-IR based calibration model. The results indicate that surface a residue of 0.19 μg cm-2 for a specific molecule is detectable using a specular reflectance Mid-IR technique.The electrocatalytic hydrogen evolution reaction (HER) has attracted substantial attention owing to its&hellip;<span class="activity-read-more" id="activity-read-more-36788"><a href="http://www.nationalboardinstitute.com/activity/p/36788/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f0422dd81e9042af117ae7c8056afd7a</guid>
				<title>Sharpe posted an update: The accumulation of amyloid-β, a metabolic residue found in [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34851/</link>
				<pubDate>Fri, 31 Jan 2025 11:48:29 -0800</pubDate>

									<content:encoded><![CDATA[<p>The accumulation of amyloid-β, a metabolic residue found in the brain, has been linked to cognitive ageing and Alzheimer&#8217;s disease. A longitudinal study reveals that the increase of amyloid-β can be predicted using simple sleep parameters.Dead museum specimens are finding new life, providing critical data about otherwise hidden impacts of h&hellip;<span class="activity-read-more" id="activity-read-more-34851"><a href="http://www.nationalboardinstitute.com/activity/p/34851/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">9ad91aea21e2897bc3b685f24eb81b2a</guid>
				<title>Sharpe posted an update: Using the tumor growth rate, 90% of all patients showed a [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/31553/</link>
				<pubDate>Tue, 28 Jan 2025 17:02:52 -0800</pubDate>

									<content:encoded><![CDATA[<p>Using the tumor growth rate, 90% of all patients showed a tumor reduction between first and final response evaluation. The 6-month, 1-, 2- and 3-year overall survival rates were 86.5%, 67.4%, 47.2%, and 33.7%, with a median survival of 45, 24, 15, and 14 months for complete response, partial response, stable disease, and progressive disease,&hellip;<span class="activity-read-more" id="activity-read-more-31553"><a href="http://www.nationalboardinstitute.com/activity/p/31553/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">34427bf3ded230f357ca61199a9d46ef</guid>
				<title>Sharpe became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/31494/</link>
				<pubDate>Tue, 28 Jan 2025 16:57:36 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>